Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:15:54.024Z.
Calculation as of: 2026-10-06T14:15:54.024Z.
Quote observation: 2026-10-06T14:15:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a667a199b47e7e336467208d2f6772290b800d1a0ab6507ee3a182ebbb9f075
PEG RATIO
N/A
Market Cap
$107.45M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$106.83M
PEG Ratio
N/A
TTM Avg
8.77
3Y Avg
19.79
5Y Avg
19.79
Market Cap
$109.64M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BGM Group Ltd. (BGM) | $112.03M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $108.33M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.91M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $108.43M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.45M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.83M | N/A | 8.77 | 19.79 | 19.79 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.64M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $105.15M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $112.13M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $105.61M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
